

09-13-04

IPW



Attorney's Docket No. 104035.269169

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Dannhardt et al
Confirmation No.: 3699
Appl. No.: 10/672,613
Art Unit: 1626
Filed: September 26, 2003
Examiner: Robin Waller
For: 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE
THEREOF AS CYCLOOXYGENASE INHIBITORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

Andrew T. Meunier
Registration No. 40,726

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Atlanta Office (404) 881-7000
Fax Atlanta Office (404) 881-7777

"Express Mail" mailing label number EV 354292910 US
Date of Deposit September 10, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Teresa Wells

Substitute for form 1449/PTO
(Revised 04/2003)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/672,613
Filing Date September 26, 2003
First Named Inventor Dannhardt et al.
Group Art Unit 1626
Examiner Name Robin Waller
Attorney Docket Number 104035.269169

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	4,269,847	05-26-1981	Niedballa et al.	
	2	4,440,776	04-03-1984	Niedballa et al.	
	3	4,686,231	08-11-1987	Bender et al.	
	4	5,364,875	11-15-1994	Wilde	
	5	5,620,999	04-15-1997	Weier et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	6	JP 01040467	02-10-1989	Hisamitsu Pharmaceut Co. Inc.		Abstract Only
	7	WO 91/10662	07-25-1991	Rhone-Poulenc Rorer S.A.		
	8	WO 91/13876	09-19-1991	Rhone-Poulenc Rorer Limited		
	9	SU 1415725 A1	01-10-1996	Katkov V.F., etc.		Abstract Only

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	10	MADUSKUIE, THOMAS P., Jr., et al., "Design, Synthesis, and Structure-Activity Relationship Studies for a New Imidazole Series of J774 Macrophage Specific Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitors," J. Med. Chem., 1995, pages 1067-1083, Vol. 38, XP001084249, American Chemical Society, U.S.A.	
	11	MUSTAFA, A., et al., "Reactions with 4,5-Disubstituted 2-Mercaptoimidazoles and their Derivatives," J. Prakt. Chem., 1972, pages 785-792, Vol. 314, XP-001088374, J. A. Barth, Leipzig.	
Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/672,613
				Filing Date	September 26, 2003
				First Named Inventor	Dannhardt et al.
				Group Art Unit	1626
				Examiner Name	Robin Waller
Sheet	2	of	2	Attorney Docket Number	104035.269169
OTHER DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			English Language Translation Attached
	12	GUPTA, G. D., et al., "Heterocyclic Systems Containing Bridgehead Nitrogen Atom. Part XLVI, Reaction of 4,5-disubstituted 2-mercaptoimidazoles with alpha-halogenoketones and 1,2-dibromoethane," Indian J. Chemical, Chemical Abstracts, August 29, 1983, Vol. 99, No. 9, Abstract No. 70631, Columbus, Ohio.			
	13	SALAMA, M.A., et al., "Synthesis and reactions of 4,5-diaryl-2-mercaptoimidazoles," Chemical Abstracts, November 7, 1988, page 710, Vol. 109, No. 19, Abstract No. 170305, Columbus, Ohio.			
	14	WILDE, RICHARD G., et al., "Acyl CoA: Cholesterol Acyltransferase (ACAT) Inhibitors: Heterocyclic Bioisosteres for the Urea Group in DuP 128," Bioorganic & Medicinal Chemistry Letters, January 19, 1995, pages 177-180, Vol. 5, No. 2, XP004135812, Elsevier Science Ltd., Great Britain.			
	15	International Search Report from corresponding International Application No. PCT/EP02/03264 dated August 2, 2002.			
Examiner Signature				Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.